Arrowhead Pharmaceuticals, Inc. (ARWR): Price and Financial Metrics
ARWR Price/Volume Stats
| Current price | $36.05 | 52-week high | $48.48 |
| Prev. close | $34.67 | 52-week low | $23.09 |
| Day low | $34.56 | Volume | 942,400 |
| Day high | $36.07 | Avg. volume | 1,096,662 |
| 50-day MA | $32.63 | Dividend yield | N/A |
| 200-day MA | $33.47 | Market Cap | 3.85B |
ARWR Stock Price Chart Interactive Chart >
ARWR POWR Grades
- ARWR scores best on the Sentiment dimension, with a Sentiment rank ahead of 79.08% of US stocks.
- ARWR's strongest trending metric is Momentum; it's been moving up over the last 179 days.
- ARWR ranks lowest in Stability; there it ranks in the 14th percentile.
ARWR Stock Summary
- Of note is the ratio of ARROWHEAD PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; just 11.53% of US stocks have a lower such ratio.
- ARWR's price/sales ratio is 13.94; that's higher than the P/S ratio of 92.39% of US stocks.
- With a year-over-year growth in debt of 223.26%, ARROWHEAD PHARMACEUTICALS INC's debt growth rate surpasses 93.65% of about US stocks.
- Stocks that are quantitatively similar to ARWR, based on their financial statements, market capitalization, and price volatility, are MORF, ANAB, INDI, PLRX, and ORMP.
- Visit ARWR's SEC page to see the company's official filings. To visit the company's web site, go to arrowheadpharma.com.
ARWR Valuation Summary
- ARWR's price/sales ratio is 14.2; this is 545.45% higher than that of the median Healthcare stock.
- Over the past 230 months, ARWR's EV/EBIT ratio has gone NA NA.
Below are key valuation metrics over time for ARWR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ARWR | 2023-05-23 | 14.2 | 8.7 | -25.8 | -26.6 |
| ARWR | 2023-05-22 | 14.3 | 8.7 | -26.0 | -26.7 |
| ARWR | 2023-05-19 | 14.2 | 8.7 | -25.8 | -26.6 |
| ARWR | 2023-05-18 | 14.2 | 8.7 | -25.8 | -26.6 |
| ARWR | 2023-05-17 | 14.5 | 8.9 | -26.4 | -27.2 |
| ARWR | 2023-05-16 | 14.7 | 9.0 | -26.8 | -27.6 |
ARWR Growth Metrics
- Its 2 year price growth rate is now at -2.39%.
- Its year over year price growth rate is now at -48.42%.
- Its 3 year revenue growth rate is now at 177.9%.
The table below shows ARWR's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 278.338 | -150.3 | -154.516 |
| 2022-09-30 | 243.231 | -136.131 | -176.063 |
| 2022-06-30 | 249.939 | -91.581 | -153.926 |
| 2022-03-31 | 263.418 | -52.344 | -111.804 |
| 2021-12-31 | 144.424 | 148.799 | -182.988 |
| 2021-09-30 | 138.287 | 171.224 | -140.848 |
ARWR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARWR has a Quality Grade of C, ranking ahead of 55.82% of graded US stocks.
- ARWR's asset turnover comes in at 0.171 -- ranking 211th of 682 Pharmaceutical Products stocks.
- COLL, CRBP, and VBIV are the stocks whose asset turnover ratios are most correlated with ARWR.
The table below shows ARWR's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.171 | 1 | -0.460 |
| 2021-03-31 | 0.153 | 1 | -0.385 |
| 2020-12-31 | 0.149 | 1 | -0.363 |
| 2020-09-30 | 0.158 | 1 | -0.397 |
| 2020-06-30 | 0.241 | 1 | -0.218 |
| 2020-03-31 | 0.303 | 1 | 0.013 |
ARWR Price Target
For more insight on analysts targets of ARWR, see our ARWR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $87.92 | Average Broker Recommendation | 1.59 (Moderate Buy) |
Arrowhead Pharmaceuticals, Inc. (ARWR) Company Bio
Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics. The company was founded in 1989 and is based in Pasadena, California.
Latest ARWR News From Around the Web
Below are the latest news stories about ARROWHEAD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARWR as an investment opportunity.
Arrowhead CEO Christopher Anzalone Addresses This 'Really Important Event' In Lung DiseaseArrowhead said Thursday a single dose of its asthma drug almost completely eliminated a troublesome protein. ARWR stock closed up a fraction. |
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi TherapeuticsPASADENA, Calif., June 01, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m. ET to discuss progress towards the company’s "20 in 25" goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiM™) platform to a total of 20 clinical stage or marketed products in the year 2025. |
After a year of 4.1% returns, Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) share price drop last week may have less of an impact on institutional investorsKey Insights Significantly high institutional ownership implies Arrowhead Pharmaceuticals' stock price is sensitive to... |
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFHPASADENA, Calif., May 23, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH). The company is currently planning a Phase 3 study to further investigate ARO-ANG3 and intends to conduct a meeting with regulatory authorities in t |
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia SyndromePASADENA, Calif., May 16, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome. The company anticipates that the primary portion of the study will be complete in the second quarter of 2024 with a data readout shortly thereafter and subsequent submissions for regulatory review and approval. |
ARWR Price Returns
| 1-mo | -12.88% |
| 3-mo | 17.08% |
| 6-mo | 12.62% |
| 1-year | 3.41% |
| 3-year | 11.09% |
| 5-year | 239.77% |
| YTD | -11.12% |
| 2022 | -38.82% |
| 2021 | -13.59% |
| 2020 | 20.97% |
| 2019 | 410.71% |
| 2018 | 237.50% |
Continue Researching ARWR
Here are a few links from around the web to help you further your research on Arrowhead Pharmaceuticals Inc's stock as an investment opportunity:Arrowhead Pharmaceuticals Inc (ARWR) Stock Price | Nasdaq
Arrowhead Pharmaceuticals Inc (ARWR) Stock Quote, History and News - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...